Stock Price, News, Quote and Profile of FORTE BIOSCIENCES INC(NASDAQ:FBRX) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

FORTE BIOSCIENCES INC

NASDAQ:FBRX (4/26/2024, 7:00:02 PM)

0.7163

-0.02 (-3.07%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap26.07M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The company is headquartered in Dallas, Texas and currently employs 9 full-time employees. The company went IPO on 2017-04-13. The firm is advancing through preclinical trials its product candidate, FB-102, which is a therapeutic molecule with potentially autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo and alopecia areata (AA). FB-102 is an antagonist of autoimmune disease pathways with the potential for a durable response. The Company’s subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Emerald Limited.